Chen Zhenhang, Quirit Dudley Jeanne, Deniston Colin, Buffalo Cosmo Z, Patra Debjani, Cao Dongdong, Hunt Julia, Rohaim Ahmed, Sengupta Debapriya, Wen Lan, Tsang Tiffany, Xie Lili, DiDonato Michael, Spraggon Glen, Clifton Matthew C, Jarrousse Nadine, Straimer Judith, Liang Bo
Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Biomedical Research, Novartis, Emeryville, CA, USA.
Nat Commun. 2025 Jul 19;16(1):6655. doi: 10.1038/s41467-025-61764-4.
Transcription and replication of the Nipah virus (NiV) are driven by the large protein (L) together with its essential co-factor phosphoprotein (P). L encodes all the viral enzymatic functions, including RNA-dependent RNA polymerase (RdRp) activity, while the tetrameric P is multi-modular. Here, we investigate the molecular mechanism of the NiV polymerase and build tools for anti-NiV drug discovery. We analyze and compare multiple cryo-EM structures of both full-length and truncated NiV polymerases from the Malaysia and Bangladesh strains. We identify two conserved loops in the polyribonucleotidyltransferase (PRNTase) domain of L and the binding between RdRp-PRNTase and CD domains. To further assess the mechanism of NiV polymerase activity, we establish a highly sensitive radioactive-labeled RNA synthesis assay and identify a back-priming activity in the NiV polymerase as well as a fluorescence and luminescent-based non-radioactive polymerase assay to enable high-throughput screening for L protein inhibitors. The combination of structural analysis and the development of both high-sensitive and high-throughput biochemical assays will enable the identification of new direct-acting antiviral candidates for treating highly pathogenic henipaviruses.
尼帕病毒(NiV)的转录和复制由大蛋白(L)及其必需的辅助因子磷蛋白(P)共同驱动。L编码所有病毒酶功能,包括RNA依赖性RNA聚合酶(RdRp)活性,而四聚体P具有多模块性。在此,我们研究了NiV聚合酶的分子机制,并构建了用于抗NiV药物发现的工具。我们分析并比较了来自马来西亚和孟加拉国毒株的全长和截短型NiV聚合酶的多个冷冻电镜结构。我们在L的多聚核糖核苷酸转移酶(PRNTase)结构域中鉴定出两个保守环以及RdRp-PRNTase与CD结构域之间的结合。为了进一步评估NiV聚合酶活性的机制,我们建立了一种高度灵敏的放射性标记RNA合成测定法,并鉴定出NiV聚合酶中的回引发活性以及一种基于荧光和发光的非放射性聚合酶测定法,以实现对L蛋白抑制剂的高通量筛选。结构分析与高灵敏度和高通量生化测定法的开发相结合,将有助于鉴定用于治疗高致病性亨尼帕病毒的新型直接作用抗病毒候选药物。